Stem Cells for Immune System Regeneration to Fight Cancer

• Post author:
• Post published:October 30, 2026
• Post category:

This proposal will define the biology of stem cell engineering to produce a cancer-fighting immune system. The immune system protects our body against most outside threats. However, it frequently fails…

Continue ReadingStem Cells for Immune System Regeneration to Fight Cancer

Hypoimmune Stem Cell–Derived Islets: A Next-Generation Cell Therapy Toward a Functional Cure for Type 1 Diabetes

• Post author:
• Post published:October 29, 2026
• Post category:

Continue ReadingHypoimmune Stem Cell–Derived Islets: A Next-Generation Cell Therapy Toward a Functional Cure for Type 1 Diabetes

Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy for Multiple Sclerosis

• Post author:
• Post published:October 29, 2026
• Post category:

Continue ReadingStem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy for Multiple Sclerosis

A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events

• Post author:
• Post published:October 29, 2026
• Post category:

Continue ReadingA First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events

Gene Therapy for Alpha-1 Anti-Trypsin Deficiency

• Post author:
• Post published:October 29, 2026
• Post category:

Continue ReadingGene Therapy for Alpha-1 Anti-Trypsin Deficiency

Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies

• Post author:
• Post published:October 29, 2026
• Post category:

Continue ReadingLate-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies

Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9

• Post author:
• Post published:October 29, 2026
• Post category:

Continue ReadingAdvancement of a myotropic, liver-detargeting therapy for LGMD2i/R9

A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia

• Post author:
• Post published:October 29, 2026
• Post category:

Continue ReadingA first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia

Microglia replacement therapy for CSF1R-related Leukoencephalopathy

• Post author:
• Post published:October 29, 2026
• Post category:

Continue ReadingMicroglia replacement therapy for CSF1R-related Leukoencephalopathy

TY1 and Semaglutide to Treat Cardiometabolic HFpEF

• Post author:
• Post published:October 29, 2026
• Post category:

Continue ReadingTY1 and Semaglutide to Treat Cardiometabolic HFpEF